about
Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesHarnessing the Microbiome to Enhance Cancer ImmunotherapyIdentification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host diseaseLack of functional selectin ligand interactions compromises long term tumor protection by CD8+ T cells.Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice.Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?T(H)17 cells in tumour immunity and immunotherapy.Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.Toll-like receptors in tumor immunotherapy.IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.Interleukin-17 and type 17 helper T cells in cancer management and research.Type 17 CD8+ T cells display enhanced antitumor immunity.Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.Treatment of lymphoma with adoptively transferred T cells.Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.Is antigen specificity the key to efficient adoptive T-cell therapy?Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferasePromoting thiol expression increases the durability of antitumor T-cell functions.Fine tuning and efficient T cell activation with stimulatory aCD3 nanoarrays.Simultaneous analysis of in vivo CD8+ T cell cytotoxicity against multiple epitopes using multicolor flow cytometry.Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children.Danger signals: Chemotherapy enhancers?Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells.Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.Protective immunity against Trypanosoma cruzi.
P2860
Q27027243-D96CDEE2-3647-47AE-904D-8F7C240AAD81Q28088598-E3B2B129-3D21-4944-8B5D-5F9F198A4689Q34033248-0E0A3F9B-A93C-4A24-9F42-0D48A916F332Q34168631-35D67EC1-6042-4286-80F6-C489ECF41F49Q34216825-38E56C1B-A963-45DE-9351-5F363AF431E5Q34448082-9DC6F867-F1E9-49AB-800F-F8A92214397AQ34557185-715B60E3-F366-4535-A50B-CFB6DAD27653Q34557953-DCCE1D92-BEA0-477F-9BD5-C1A753DD1C7AQ35594089-DF65AEB8-663B-4889-A61F-20A4E41255D5Q35623903-5F9536E0-2ECE-443D-BFF6-9718F8A9C8B7Q35752854-D00287AC-C47E-46CF-9795-5BA0F5922A34Q36121187-5AFC6371-E027-42CF-BBE6-ADB991D53F14Q36253608-49C61F93-1FA8-4957-96A7-FBDB33BF01C5Q36677310-FC53BE65-8B7C-4BA8-BF35-9E6DE834E51FQ36678607-44290BC6-FCCF-4913-9FF9-2B7749B67E21Q36801053-000CE371-00D2-489A-B24C-6272A20A2EA6Q37031654-4D80DCE5-FC13-459B-80F8-C4D30FCA4F27Q37268980-904E5D16-A61A-4962-A4C5-6C584E4FBAC8Q37334596-2B844516-EF3F-4382-A3AC-AA3CA7A3A2F1Q37389018-CE03E4A0-5862-452D-BAD8-A8576EEF59B9Q37419728-BA5E34FD-8F5A-422A-80F0-385F842E95F5Q37587713-BFBA5DB6-4AB0-4D38-8A29-A2A9DD784877Q37861214-D7EA3AC2-CD52-485E-863A-FE47F63B05C4Q38289283-A52F0296-DEC4-4D74-BB78-D227578F6263Q39576904-CA59FF6D-0FBD-4DD6-B73D-BBA8A5996415Q42549343-9046C507-E821-4642-B89D-4574E46966B9Q42876926-4AAA4284-D8FE-4F2C-AB79-22DA87B9BA46Q43976553-22EF80D8-8F3E-45B8-90AF-48E06DC29071Q46202971-C4CD9D0E-3795-461E-B437-26320980D226Q47659090-D59BA7A4-686B-44CD-A0A6-7AB8942AEE0FQ49246137-8565ECD1-6BD7-418C-9538-42528FD23FB6Q50994319-55C21BEF-58B1-44EA-BD5A-E995BAC95A1CQ51890237-939CB8DA-836F-487B-9878-024F4FCC2294
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Programming CD8+ T cells for effective immunotherapy.
@ast
Programming CD8+ T cells for effective immunotherapy.
@en
Programming CD8+ T cells for effective immunotherapy.
@nl
type
label
Programming CD8+ T cells for effective immunotherapy.
@ast
Programming CD8+ T cells for effective immunotherapy.
@en
Programming CD8+ T cells for effective immunotherapy.
@nl
prefLabel
Programming CD8+ T cells for effective immunotherapy.
@ast
Programming CD8+ T cells for effective immunotherapy.
@en
Programming CD8+ T cells for effective immunotherapy.
@nl
P2860
P1476
Programming CD8+ T cells for effective immunotherapy
@en
P2093
Christian S Hinrichs
Luca Gattinoni
P2860
P304
P356
10.1016/J.COI.2006.03.009
P577
2006-04-17T00:00:00Z